Savara Inc. Common Stock (SVRA) Stock
Key stats
- Market cap
- $1.10B
- Price / Earnings ratio
- -7.1x
- EPS (TTM)
- -$0.61
- Volume
- Loading
- 52-week high
- $7.01
- 52-week low
- $4.00
Source: third-party data provider, as of November 13, 2026
Compare with SVRA
Recent news

Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
SVRA

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
SVRA

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
SVRA

Savara Announces New Employment Inducement Grant
Savara Announces New Employment Inducement Grant
SVRA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 53.89
- MACD 12/26/9
- -0.01
- EMA 9 of MACD
- -0.06
- MACD histogram
- 0.05
- SMA 50
- $4.96
- Price above SMA 50
- EMA 50
- $4.95
- Price above EMA 50
- SMA 200
- $5.34
- Price below SMA 200
- EMA 200
- $5.31
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
SVRA

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
SVRA

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
SVRA

Savara Announces New Employment Inducement Grant
Savara Announces New Employment Inducement Grant
SVRA

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
SVRA

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
SVRA

Here's Why You Should Add Savara Stock to Your Portfolio Now
Here's Why You Should Add Savara Stock to Your Portfolio Now
SVRA

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
SVRA

Savara Announces New Employment Inducement Grant
Savara Announces New Employment Inducement Grant
SVRA

Savara Announces Chief Financial and Administrative Officer Transition
Savara Announces Chief Financial and Administrative Officer Transition
SVRA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Savara Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Matthew Pauls J.D., M.B.A. | Chairman & CEO | 1971 |
| Mr. Robert Matthew Lutz M.B.A. | COO & CFO | 1969 |
| Dr. Yasmine Wasfi M.D., Ph.D. | Chief Medical Officer | — |
| Ms. Kate McCabe J.D. | Chief Legal Officer | 1986 |
| Ms. Megan Carpenter | Chief People Officer | — |
| Ms. Anne Erickson | Chief Business & Corporate Affairs Officer | 1972 |
| Brian Maurer | Head of Clinical Operations | — |
| Mr. Charles LaPree | Executive VP & Head of Global Regulatory Affairs | — |
| Dr. Brian Robinson M.D. | Executive Vice President of Global Medical Affairs | — |
| Dr. Siddharth J. Advant Ph.D. | Executive Vice President of Global Technical Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 53.89
- MACD 12/26/9
- -0.01
- EMA 9 of MACD
- -0.06
- MACD histogram
- 0.05
- SMA 50
- $4.96
- Price above SMA 50
- EMA 50
- $4.95
- Price above EMA 50
- SMA 200
- $5.34
- Price below SMA 200
- EMA 200
- $5.31
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $12.00
- Average
- $12.00
- High
- $12.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -5.3 | +14.8 | ||||||||||
| 2022 | -9.6 | -6.5 | +13.9 | -10.6 | +11.0 | +16.0 | +5.2 | -14.9 | +9.9 | -20.1 | +33.9 | -0.6 |
| 2023 | +62.5 | +0.0 | -21.4 | +2.7 | +44.0 | +9.2 | +12.9 | +1.4 | -1.6 | +2.8 | +5.5 | +20.5 |
| 2024 | +13.0 | -0.2 | -3.5 | -5.4 | -17.4 | -0.5 | -0.9 | -5.9 | +0.7 | -8.8 | -6.7 | -7.3 |
| 2025 | -12.1 | -11.1 | +19.4 | +11.9 | -30.1 | -5.0 | +26.3 | +26.6 | +7.9 | +17.2 | +47.3 | +3.3 |
| 2026 | -4.3 | +9.1 | -9.2 | -6.1 | +1.6 | +19.6 | -9.9 | +1.1 | -3.6 | -4.6 | +5.5 |



